Skip to main content
$1.46 -$0.07 (-4.7%)

03:58 PM EDT on 06/09/23

Nabriva Therapeutics (NASDAQ:NBRV)

CAPS Rating: No stars

Current Price $1.46 Mkt Cap $4.7M
Open $1.50 P/E Ratio -0.08
Prev. Close $1.46 Div. (Yield) $0.00 (0.0%)
Daily Range $1.45 - $1.50 Volume 9,634
52-Wk Range $1.22 - $8.45 Avg. Daily Vol. 14,563


This ticker is not currently Ratable.

Add Stock to CAPS Watchlist

All Players

17 Outperform
2 Underperform

All-Star Players

3 Outperform
2 Underperform

Wall Street

0 Outperform
0 Underperform

Top NASDAQ:NBRV Bull/Bear Pitches

The best Bull and Bear pitches based on recency and number of recommendations.

Top Bull Pitch

There are no pitches that meet the Top Bull criteria. Explain

If this upsets you, start recommending pitches below!

Top Bear Pitch

There are no pitches that meet the Top Bear criteria. Explain

If this upsets you, start recommending pitches below!


Fools bullish on NASDAQ:NBRV are also bullish on:

Fools bearish on NASDAQ:NBRV are also bearish on:

Recent Community Commentary

Read the most recent pitches from players about NBRV.


Member Avatar HealthNut777 (< 20) Submitted: 8/11/2021 9:18:30 PM : Outperform Start Price: $5.74 NASDAQ:NBRV Score: -86.15

Currently, NBRV has 2 FDA drugs to sell; will soon have 3 FDA wonder drugs to sell. Drugs are ultra-valuable, versatile, safe and effective so these drugs will save millions of lives worldwide. This is the DD that convinced me to invest $10K, YOLO: Astute Reddit poster seems spot on to me and even my entire family knows the antibiotic resistance problem in US & spreading across the planet.


Member Avatar MamaT3 (< 20) Submitted: 4/2/2020 9:40:46 PM : Outperform Start Price: $0.51 NASDAQ:NBRV Score: +118.21

Something to watch


Member Avatar AndrewGreenBull (88.39) Submitted: 8/19/2019 11:22:35 PM : Outperform Start Price: $2.40 NASDAQ:NBRV Score: -83.04

NBRV is a good bargin under $3

My takes:

· Xenleta: 5million cases in US, 5-7days course of therapy, $205/275 per treatment day—that is a $6 billion dollars potential market.

· 200 million Market cap is way below its fair value (73 million shares with a price of $2.7 , after market price). The company has a robust pipeline besides Xenleta. CONTEPO will be the next one up for FDA approval. It received CRL in may, but the issue that FDA pointed out was minor. Facility inspections and manufacturing deficiencies at one of its contract manufacturers can be fixed. The FDA did not request any new clinical data or raise any safety concerns. It will be resubmitted for NDA early next quarter, and expected next PDUFA in six months after submission.

· NBRV signed a deal with a Chinese company in 2018 to sell in China, where has bigger market than the US.

“Under the terms of the agreement Roivant Sciences of Hong Kong will make an upfront payment of $5 million to Nabriva, which is based in Dublin, Ireland, and has its U.S. headquarters in King of Prussia. Narbiva (NASDAQ: NBRV) would be eligible for additional payments, described as "about $90 million," tied to achieving milestones related to the development of its new drug candidate Lefamulin. If the product is approved in China, Nabriva would also receive royalty payments.”

· The company has about 74 million cash, cash equivalents and short-term investments and existing cash resources are expected to fund operations into the second quarter of 2020 according to its recent quarterly report. That means no public offering in the near term.


Find the members with the highest scoring picks in NBRV.

Score Leader


HDTVBG (< 20) Score: +163.27

Highly dilutive secondary offering just turned all longs into bag holders. Hedge funds to the rescue ???

Member Name Member
Call Time
Score Commentary
MamaT3 < 20 4/3/2020 Outperform 5Y $0.51 +189.22% +71.01% +118.21 1 Comment
zzlangerhans 99.30 3/18/2019 Underperform 1Y $2.88 -48.58% +52.74% +101.33 0 Comment
drugtrader 61.04 6/25/2020 Outperform 5Y $0.74 +99.30% +41.16% +58.14 0 Comment
nastyadam < 20 6/1/2020 Outperform 3M $0.80 +85.80% +40.59% +45.21 0 Comment
LifeScientist < 20 6/15/2020 Outperform 3W $0.92 +60.97% +40.18% +20.79 0 Comment
Magistore < 20 6/18/2020 Outperform 3W $0.94 +57.63% +38.55% +19.08 0 Comment
MichaelDFS 94.92 5/29/2020 Outperform 1Y $0.98 +51.15% +42.70% +8.45 0 Comment
samarai212 45.35 4/15/2021 Outperform 5Y $1.52 -2.58% +3.94% -6.52 0 Comment
ColombiaClub 82.84 7/29/2020 Underperform 5Y $0.80 +85.10% +33.50% -51.60 0 Comment
roaringKitty < 20 2/19/2021 Outperform NS $3.11 -52.39% +9.69% -62.07 0 Comment

Wall Street

See what the Wall Street professionals think, according to their public statements and filings.

There are no Wall Street tracker picks for NBRV.